EGAPP|Working Group|Recommendations

EGAPP Working Group Recommendations

Disease/Condition	Genetic Test/Purpose	Test Use	EGAPP™ Recommendation
Breast Cancer:	Can tumor gene expression profiling improve outcomes in patients with breast cancer?	Prognostic: association of genetic markers with disease severity, progression	Insufficient evidence to recommend for or against use Read the EGAPP recommendation [PDF 455 KB] (January 2009)
Cardiovascular Disease:	Recommendations from the EGAPP Working Group: Genomic profiling to assess cardiovascular risk to improve cardiovascular health	Prediction: association of genetic markers with disease risk	Insufficient evidence to recommend for or against use Read the EGAPP recommendation (December 2010)
	Genetic testing for Factor V Leiden and prothrombin variants for idiopathic venous thromboembolism (VTE)	Diagnostic: association of a genetic marker with a disease/condition in a person with symptoms and family members without symptoms	Sufficient evidence to recommend against routine use in adults with idiopathic VTE; and in their adult family members with no history or symptoms of thrombotic events, for medical decision making on preventive use of anticoagulants Read the EGAPP recommendation (January 2011)
Colorectal Cancer:	Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives	Diagnostic: association of a genetic marker with a disease/condition in a person with symptoms	Sufficient evidence to recommend use for the benefit of relatives Read the EGAPP recommendation [PDF 220 KB] (January 2009)
	Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer?	Pharmacogenomic: predicting response to drug treatment	Insufficient evidence to recommend for or against use Read the EGAPP recommendation [PDF 201 KB] (January 2009)
Depression:	Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors	Pharmacogenomic: predicting response to drug treatment	Insufficient evidence to recommend for or against use, but use discouraged pending further research Read the EGAPP recommendation [PDF 225 KB] (December 2007)

Page last updated: July 20, 2012
Page last reviewed: July 20, 2012
Content Source: EGAPP Team